Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

18F-FDG PET/CT-based early treatment response evaluation of nanoparticle-assisted photothermal cancer therapy

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Norregaard, Kamilla ; Jørgensen, Jesper T ; Simón, Marina ; Melander, Fredrik ; Kristensen, Lotte K ; Bendix, Pól M ; Andresen, Thomas L ; Oddershede, Lene B ; Kjaer, Andreas. / 18F-FDG PET/CT-based early treatment response evaluation of nanoparticle-assisted photothermal cancer therapy. In: P L o S One. 2017 ; Vol. 12, No. 5. pp. e0177997.

Bibtex

@article{5884144ce9214d1d8352fca332c92b62,
title = "18F-FDG PET/CT-based early treatment response evaluation of nanoparticle-assisted photothermal cancer therapy",
abstract = "Within the field of nanoparticle-assisted photothermal cancer therapy, focus has mostly been on developing novel heat-generating nanoparticles with the right optical and dimensional properties. Comparison and evaluation of their performance in tumor-bearing animals are commonly assessed by changes in tumor volume; however, this is usually a late-occurring event. This study implements 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging to perform early evaluation of the treatment outcome of photothermal therapy. Silica-gold nanoshells (NS) are administered intravenously to nude mice bearing human neuroendocrine tumor xenografts and the tumors are irradiated by a near-infrared laser. The animals are positron emission tomography scanned with 2-deoxy-2-[F-18]fluoro-D-glucose one day before and one day after treatment. Using this setup, a significant decrease in tumor uptake of 2-deoxy-2-[F-18]fluoro-D-glucose is found already one day after therapy in the group receiving NS and laser treatment compared to control animals. At this time point no change in tumor volume can be detected. Moreover, the change in tumor uptake, is used to stratify the animals into responders and non-responders, where the responding group matched improved survival. Overall, these findings support the use of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for preclinical and clinical evaluation and optimization of photothermal therapy.",
keywords = "Animals, Cell Line, Tumor, Disease Models, Animal, Female, Fluorodeoxyglucose F18, Humans, Metal Nanoparticles, Mice, Mice, Nude, Neoplasms, Photochemotherapy, Positron Emission Tomography Computed Tomography, Treatment Outcome, Xenograft Model Antitumor Assays, Journal Article",
author = "Kamilla Norregaard and J{\o}rgensen, {Jesper T} and Marina Sim{\'o}n and Fredrik Melander and Kristensen, {Lotte K} and Bendix, {P{\'o}l M} and Andresen, {Thomas L} and Oddershede, {Lene B} and Andreas Kjaer",
year = "2017",
month = may,
doi = "10.1371/journal.pone.0177997",
language = "English",
volume = "12",
pages = "e0177997",
journal = "PLOS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

RIS

TY - JOUR

T1 - 18F-FDG PET/CT-based early treatment response evaluation of nanoparticle-assisted photothermal cancer therapy

AU - Norregaard, Kamilla

AU - Jørgensen, Jesper T

AU - Simón, Marina

AU - Melander, Fredrik

AU - Kristensen, Lotte K

AU - Bendix, Pól M

AU - Andresen, Thomas L

AU - Oddershede, Lene B

AU - Kjaer, Andreas

PY - 2017/5

Y1 - 2017/5

N2 - Within the field of nanoparticle-assisted photothermal cancer therapy, focus has mostly been on developing novel heat-generating nanoparticles with the right optical and dimensional properties. Comparison and evaluation of their performance in tumor-bearing animals are commonly assessed by changes in tumor volume; however, this is usually a late-occurring event. This study implements 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging to perform early evaluation of the treatment outcome of photothermal therapy. Silica-gold nanoshells (NS) are administered intravenously to nude mice bearing human neuroendocrine tumor xenografts and the tumors are irradiated by a near-infrared laser. The animals are positron emission tomography scanned with 2-deoxy-2-[F-18]fluoro-D-glucose one day before and one day after treatment. Using this setup, a significant decrease in tumor uptake of 2-deoxy-2-[F-18]fluoro-D-glucose is found already one day after therapy in the group receiving NS and laser treatment compared to control animals. At this time point no change in tumor volume can be detected. Moreover, the change in tumor uptake, is used to stratify the animals into responders and non-responders, where the responding group matched improved survival. Overall, these findings support the use of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for preclinical and clinical evaluation and optimization of photothermal therapy.

AB - Within the field of nanoparticle-assisted photothermal cancer therapy, focus has mostly been on developing novel heat-generating nanoparticles with the right optical and dimensional properties. Comparison and evaluation of their performance in tumor-bearing animals are commonly assessed by changes in tumor volume; however, this is usually a late-occurring event. This study implements 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging to perform early evaluation of the treatment outcome of photothermal therapy. Silica-gold nanoshells (NS) are administered intravenously to nude mice bearing human neuroendocrine tumor xenografts and the tumors are irradiated by a near-infrared laser. The animals are positron emission tomography scanned with 2-deoxy-2-[F-18]fluoro-D-glucose one day before and one day after treatment. Using this setup, a significant decrease in tumor uptake of 2-deoxy-2-[F-18]fluoro-D-glucose is found already one day after therapy in the group receiving NS and laser treatment compared to control animals. At this time point no change in tumor volume can be detected. Moreover, the change in tumor uptake, is used to stratify the animals into responders and non-responders, where the responding group matched improved survival. Overall, these findings support the use of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for preclinical and clinical evaluation and optimization of photothermal therapy.

KW - Animals

KW - Cell Line, Tumor

KW - Disease Models, Animal

KW - Female

KW - Fluorodeoxyglucose F18

KW - Humans

KW - Metal Nanoparticles

KW - Mice

KW - Mice, Nude

KW - Neoplasms

KW - Photochemotherapy

KW - Positron Emission Tomography Computed Tomography

KW - Treatment Outcome

KW - Xenograft Model Antitumor Assays

KW - Journal Article

U2 - 10.1371/journal.pone.0177997

DO - 10.1371/journal.pone.0177997

M3 - Journal article

C2 - 28542311

VL - 12

SP - e0177997

JO - PLOS ONE

JF - PLOS ONE

SN - 1932-6203

IS - 5

ER -

ID: 52705699